fda semaglutide warning september 2025 The U.S. Food and Drug Administration (FDA) has issued a to Novo Nordisk over its alleged failure to report adverse side effects, including death, in patients who took its GLP-1 medications FDA Adds New Warnings to

However, the exact benefits vary by the individual, the specific medicine used, and whether the person can continue treatment safely over time

Every incorrect dose, whether too high or too low, disrupts the steady-state blood levels that drive these outcomes

Many women are prescribed Mounjaro during perimenopause or menopause as part of obesity or weight-management treatment

I started taking evening walks that turned into light jogs

Heart and kidney health and GLP-1s The reason that medical experts recommend weight loss to certain people in the first place is because having overweight or obesity is linked to a higher risk for serious health issues